Article in Molecules (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.2field-weighted citation impact, top 54% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
4 citing papers in PubMed, 7 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
13 authors at 4 institutions in 2 countries.
Bernhard SattlerDepartment of Nuclear Medicine, University Hospital Leipzig, 04103 Leipzig, Germany.ORCID 0000-0003-3862-2609
Mathias KranzHelmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, Department of Neuroradiopharmaceuticals, 04318 Leipzig, Germany.ORCID 0000-0002-5641-7396
Barbara WenzelHelmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, Department of Neuroradiopharmaceuticals, 04318 Leipzig, Germany.ORCID 0000-0001-7390-3575
Nalin T JainHelmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, Department of Neuroradiopharmaceuticals, 04318 Leipzig, Germany.
Rareş-Petru MoldovanHelmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, Department of Neuroradiopharmaceuticals, 04318 Leipzig, Germany.ORCID 0000-0003-3119-7945
Magali ToussaintHelmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, Department of Neuroradiopharmaceuticals, 04318 Leipzig, Germany.
Winnie Deuther-ConradHelmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, Department of Neuroradiopharmaceuticals, 04318 Leipzig, Germany.ORCID 0000-0003-3168-3062
Friedrich-Alexander LudwigHelmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, Department of Neuroradiopharmaceuticals, 04318 Leipzig, Germany.
Rodrigo TeodoroHelmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, Department of Neuroradiopharmaceuticals, 04318 Leipzig, Germany.ORCID 0000-0002-1425-0567
Tatjana SattlerDepartment of Claw Animals, University of Leipzig, 04103 Leipzig, Germany.
Masoud SadeghzadehHelmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, Department of Neuroradiopharmaceuticals, 04318 Leipzig, Germany.ORCID 0000-0002-6844-6637
Osama SabriDepartment of Nuclear Medicine, University Hospital Leipzig, 04103 Leipzig, Germany.
Peter BrustHelmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, Department of Neuroradiopharmaceuticals, 04318 Leipzig, Germany.ORCID 0000-0001-5555-7058
Helmholtz-Zentrum Dresden-Rossendorf · DEUniversity Hospital Leipzig · DELeipzig University · DEUniversity Hospital of North Norway · NO
Funding
Strahlenschutzseminar in Thueringen e.V. F2015-06
6 · The paper itself
Abstract
Overexpression of monocarboxylate transporters (MCTs) has been shown for a variety of human cancers (e.g., colon, brain, breast, and kidney) and inhibition resulted in intracellular lactate accumulation, acidosis, and cell death. Thus, MCTs are promising targets to investigate tumor cancer metabolism with positron emission tomography (PET). Here, the organ doses (ODs) and the effective dose (ED) of the first
Indexed as
AnimalsBone MarrowFluorine RadioisotopesMonocarboxylate Transport Protein 1Monocarboxylic Acid TransportersNeoplasmsPositron Emission Tomography Computed TomographyRadiometryRadiopharmaceuticalsStomachSwineSymportersTissue DistributionTomography, X-Ray ComputedUrinary BladderFluorine RadioisotopesMonocarboxylate Transport Protein 1Monocarboxylic Acid TransportersRadiopharmaceuticalsSymporters[18F]FACHimage-based internal dosimetryMCT1/MCT4 lactate transporter inhibitorOLINDApreclinical radiopharmaceutical dosimetryradiation safety
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Preclinical Incorporation Dosimetry of [ · full record | OpenQuestion